MDL-811

MDL-811
Clinical data
Drug class	Sirtuin-6 (SIRT6) activator
Identifiers
	IUPAC name N-(5-bromo-4-fluoro-2-methylphenyl)-4-[(3,5-dichlorophenyl)sulfonylamino]-2-[[(3R)-3-methylmorpholin-4-yl]methyl]benzenesulfonamide;
CAS Number	2275619-98-0;
PubChem CID	169450636;
ChemSpider	129309230;
ChEMBL	ChEMBL5275868;
Chemical and physical data
Formula	C25H25BrCl2FN3O5S2
Molar mass	681.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1COCCN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl)S(=O)(=O)NC4=CC(=C(C=C4C)F)Br;
	InChI InChI=1S/C25H25BrCl2FN3O5S2/c1-15-7-23(29)22(26)12-24(15)31-39(35,36)25-4-3-20(8-17(25)13-32-5-6-37-14-16(32)2)30-38(33,34)21-10-18(27)9-19(28)11-21/h3-4,7-12,16,30-31H,5-6,13-14H2,1-2H3/t16-/m1/s1; Key:ULBHGKXUHYSORN-MRXNPFEDSA-N;

MDL-811 is a drug which acts as a sirtuin-6 (SIRT6) activator. It has antiinflammatory effects and shows neuroprotective effects in animal models of stroke and heart attack.^[1]^[2]^[3]^[4]

References

^ Shang J, Zhu Z, Chen Y, Song J, Huang Y, Song K, et al. (2020). "Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D₃ in colorectal cancer". Theranostics. 10 (13): 5845–5864. doi:10.7150/thno.44043. PMC 7255010. PMID 32483423.
^ He T, Shang J, Gao C, Guan X, Chen Y, Zhu L, et al. (March 2021). "A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis". Acta Pharmaceutica Sinica. B. 11 (3): 708–726. doi:10.1016/j.apsb.2020.11.002. PMC 7982432. PMID 33777677.
^ Ren SC, Chen X, Gong H, Wang H, Wu C, Li PH, et al. (July 2022). "SIRT6 in Vascular Diseases, from Bench to Bedside". Aging and Disease. 13 (4): 1015–1029. doi:10.14336/AD.2021.1204. PMC 9286919. PMID 35855341.
^ Yu XT, Zhao N, Ma YT, Jia JM, Song YT, Liu XY, et al. (September 2025). "Sirtuin 6 mitigates thoracic aortic aneurysm progression via maintenance of mitochondria homeostasis in vascular smooth muscle cells". Acta Pharmacologica Sinica. doi:10.1038/s41401-025-01628-1. PMID 40897853.